Two Ground-Breaking Therapies Approved for Patients
June 14, 2019
Watch the first gene therapy vlog by Pall’s gene therapy expert, Dr Clive Glover.
In this vlog, Clive shares his thoughts and insights regarding two important pieces of recent gene therapy news.
First was the announcement on May 31 of the approval of Zolgensma♦, for the treatment of spinal muscular atrophy (SMA) in the US. The second was the announcement on the June 3 that Zynteglo♦ has been approved in Europe for the treatment of beta thalassemia (a blood disorder that reduces the production of haemoglobin).
“A lot of the headlines around these approvals focused on the pricing of these particular drugs and indeed, they are very expensive. But I think that that those headlines sort of missed the point in many ways because these are in fact, really ground-breaking therapies that will have true benefits for many patients where they were previously very limited options.”
Listen to the full vlog here:
Learn more about gene therapy in the next blog: Top Industrialization Challenges of Gene Therapy Manufacturing.
♦ Zolgensma is a trademark of AveXis Inc., Zynteglo is a trademark of Bluebird Bio Ltd.
Clive Glover – Director, Cell & Gene Therapy
- Sort By